Thermo Fisher’s revenues
Thermo Fisher Scientific (TMO) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during Q2 2018 and reported non-GAAP EPS of $2.75 on revenues of ~$6.1 billion during the quarter. The above chart compares the revenues since the first quarter of 2017.
Revenues for Q2
Thermo Fisher reported 21.8% growth in revenues to $6.1 billion during Q2 2018 as compared to $5.0 billion during the second quarter of 2017. The growth includes 8% growth in organic revenues, 12% growth driven by acquisitions, and a 2% favorable impact of foreign exchange during the quarter.
Thermo Fisher provides analytical instruments, equipment, reagents, consumables, software, and services for pharmaceutical, biotech, healthcare, diagnostics, academics, and government agencies. The growth during Q2 2018 was driven by strong performances across all four segments including Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
The revenues for Life Sciences Solutions increased ~25.8% YoY to ~$1.6 billion during the second quarter of 2018, while the revenues for Analytical Instruments increased by 21.6% YoY to ~$1.3 billion during the quarter. The Specialty Diagnostics segment reported 15.3% growth in YoY revenues to $932 million, and revenues for Laboratory Products and Services increased by 42.0% YoY to ~$2.5 billion during the quarter.
Revenues for H1 2018
During H1 2018, Thermo Fisher reported 22.3% growth in revenues to $11,931 million as compared to revenues of $9,755 million during the first half of 2017.
The Health Care Select Sector SPDR ETF (XLV) holds 2.7% of its total investments in Thermo Fisher Scientific (TMO), 3.3% in Abbott Laboratories (ABT), 3.6% in Medtronic (MDT), and 1.9% in Becton Dickinson (BDX).